Cargando…
Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells
The FcRH4 transmembrane molecule, a member of the Fc receptor homologue family, can potently inhibit B cell receptor (BCR) signaling. We show that cell surface expression of this immunoregulatory molecule is restricted to a subpopulation of memory B cells, most of which lack the classical CD27 marke...
Autores principales: | Ehrhardt, Götz R.A., Hsu, Joyce T., Gartland, Lanier, Leu, Chuen-Miin, Zhang, Shuangyin, Davis, Randall S., Cooper, Max D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212938/ https://www.ncbi.nlm.nih.gov/pubmed/16157685 http://dx.doi.org/10.1084/jem.20050879 |
Ejemplares similares
-
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
por: Stewart, A. Keith, et al.
Publicado: (2019) -
Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma
por: Jiang, Dongpeng, et al.
Publicado: (2023) -
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
por: Li, Ji, et al.
Publicado: (2017) -
Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties
por: Ovacik, Ayse Meric, et al.
Publicado: (2018) -
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
por: Zhao, Juanjuan, et al.
Publicado: (2023)